vs
Ginkgo Bioworks Holdings, Inc.（DNA）与R F INDUSTRIES LTD（RFIL）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是R F INDUSTRIES LTD的1.5倍（$33.4M vs $22.7M），R F INDUSTRIES LTD同比增速更快（22.9% vs -23.8%），R F INDUSTRIES LTD自由现金流更多（$2.0M vs $-47.7M），过去两年R F INDUSTRIES LTD的营收复合增速更高（29.8% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
妥思卷工业是一家总部位于美国伊利诺伊州芝加哥的糖果制造商，旗下最知名的产品包括同名的Tootsie Roll软糖以及Tootsie Pop棒棒糖，目前其品牌产品销往加拿大、墨西哥等全球超过75个国家。
DNA vs RFIL — 直观对比
营收规模更大
DNA
是对方的1.5倍
$22.7M
营收增速更快
RFIL
高出46.8%
-23.8%
自由现金流更多
RFIL
多$49.7M
$-47.7M
两年增速更快
RFIL
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $22.7M |
| 净利润 | — | $173.0K |
| 毛利率 | — | 36.8% |
| 营业利润率 | -211.9% | 4.0% |
| 净利率 | — | 0.8% |
| 营收同比 | -23.8% | 22.9% |
| 净利润同比 | — | 172.7% |
| 每股收益（稀释后） | $-1.41 | $0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARFIL
| Q4 25 | $33.4M | $22.7M | ||
| Q3 25 | $38.8M | $19.8M | ||
| Q2 25 | $49.6M | $18.9M | ||
| Q1 25 | $48.3M | $19.2M | ||
| Q4 24 | $43.8M | $18.5M | ||
| Q3 24 | $89.0M | $16.8M | ||
| Q2 24 | $56.2M | $16.1M | ||
| Q1 24 | $37.9M | $13.5M |
净利润DNARFIL
| Q4 25 | — | $173.0K | ||
| Q3 25 | $-80.8M | $392.0K | ||
| Q2 25 | $-60.3M | $-245.0K | ||
| Q1 25 | $-91.0M | $-245.0K | ||
| Q4 24 | — | $-238.0K | ||
| Q3 24 | $-56.4M | $-705.0K | ||
| Q2 24 | $-217.2M | $-4.3M | ||
| Q1 24 | $-165.9M | $-1.4M |
毛利率DNARFIL
| Q4 25 | — | 36.8% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 31.5% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | — | 29.9% | ||
| Q1 24 | — | 24.5% |
营业利润率DNARFIL
| Q4 25 | -211.9% | 4.0% | ||
| Q3 25 | -231.8% | 3.6% | ||
| Q2 25 | -132.1% | 0.6% | ||
| Q1 25 | -184.1% | 0.3% | ||
| Q4 24 | -236.3% | 0.5% | ||
| Q3 24 | -62.0% | -2.5% | ||
| Q2 24 | -396.7% | -2.6% | ||
| Q1 24 | -469.1% | -15.5% |
净利率DNARFIL
| Q4 25 | — | 0.8% | ||
| Q3 25 | -207.9% | 2.0% | ||
| Q2 25 | -121.6% | -1.3% | ||
| Q1 25 | -188.2% | -1.3% | ||
| Q4 24 | — | -1.3% | ||
| Q3 24 | -63.3% | -4.2% | ||
| Q2 24 | -386.4% | -26.7% | ||
| Q1 24 | -437.3% | -10.1% |
每股收益（稀释后）DNARFIL
| Q4 25 | $-1.41 | $0.01 | ||
| Q3 25 | $-1.45 | $0.04 | ||
| Q2 25 | $-1.10 | $-0.02 | ||
| Q1 25 | $-1.68 | $-0.02 | ||
| Q4 24 | $-1.91 | $-0.02 | ||
| Q3 24 | $-1.08 | $-0.07 | ||
| Q2 24 | $-4.23 | $-0.41 | ||
| Q1 24 | $-3.32 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $5.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $35.2M |
| 总资产 | $1.1B | $73.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNARFIL
| Q4 25 | $422.6M | $5.1M | ||
| Q3 25 | $495.5M | $3.0M | ||
| Q2 25 | $559.4M | $3.6M | ||
| Q1 25 | $325.3M | $1.3M | ||
| Q4 24 | $561.6M | $839.0K | ||
| Q3 24 | $616.2M | $1.8M | ||
| Q2 24 | $730.4M | $1.4M | ||
| Q1 24 | $840.4M | $4.5M |
股东权益DNARFIL
| Q4 25 | $508.6M | $35.2M | ||
| Q3 25 | $559.8M | $34.8M | ||
| Q2 25 | $613.0M | $34.2M | ||
| Q1 25 | $647.4M | $34.2M | ||
| Q4 24 | $716.1M | $34.1M | ||
| Q3 24 | $797.9M | $34.1M | ||
| Q2 24 | $833.1M | $34.6M | ||
| Q1 24 | $987.3M | $38.7M |
总资产DNARFIL
| Q4 25 | $1.1B | $73.0M | ||
| Q3 25 | $1.2B | $73.2M | ||
| Q2 25 | $1.2B | $72.7M | ||
| Q1 25 | $1.3B | $70.4M | ||
| Q4 24 | $1.4B | $71.0M | ||
| Q3 24 | $1.5B | $71.9M | ||
| Q2 24 | $1.6B | $72.8M | ||
| Q1 24 | $1.6B | $79.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $2.1M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $2.0M |
| 自由现金流率自由现金流/营收 | -142.8% | 9.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 12.13× |
| 过去12个月自由现金流最近4个季度 | — | $4.3M |
8季度趋势，按日历期对齐
经营现金流DNARFIL
| Q4 25 | $-47.7M | $2.1M | ||
| Q3 25 | $-31.6M | $-311.0K | ||
| Q2 25 | $-40.3M | $2.2M | ||
| Q1 25 | $-51.5M | $601.0K | ||
| Q4 24 | $-42.4M | $-244.0K | ||
| Q3 24 | $-103.5M | $2.4M | ||
| Q2 24 | $-84.4M | $197.0K | ||
| Q1 24 | $-89.3M | $840.0K |
自由现金流DNARFIL
| Q4 25 | $-47.7M | $2.0M | ||
| Q3 25 | — | $-419.0K | ||
| Q2 25 | $-40.3M | $2.2M | ||
| Q1 25 | $-59.1M | $574.0K | ||
| Q4 24 | $-56.1M | $-418.0K | ||
| Q3 24 | $-118.6M | $2.1M | ||
| Q2 24 | $-111.4M | $28.0K | ||
| Q1 24 | $-96.0M | $697.0K |
自由现金流率DNARFIL
| Q4 25 | -142.8% | 9.0% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | -81.2% | 11.4% | ||
| Q1 25 | -122.4% | 3.0% | ||
| Q4 24 | -128.0% | -2.3% | ||
| Q3 24 | -133.2% | 12.6% | ||
| Q2 24 | -198.2% | 0.2% | ||
| Q1 24 | -252.9% | 5.2% |
资本支出强度DNARFIL
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 15.8% | 0.1% | ||
| Q4 24 | 31.3% | 0.9% | ||
| Q3 24 | 16.9% | 1.5% | ||
| Q2 24 | 48.1% | 1.0% | ||
| Q1 24 | 17.7% | 1.1% |
现金转化率DNARFIL
| Q4 25 | — | 12.13× | ||
| Q3 25 | — | -0.79× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
